Publications

• Debevoise & Plimpton Special Committee Report Issue 12
  August 2026
  Erik J. Andrén
  ,
  Spencer K. Gilbert
  ,
  Elliot Greenfield
  ,
  Emily F. Huang
  ,
  Jonathan E. Levitsky
  ,
  Gordon Moodie
  ,
  Maeve O'Connor
  ,
  William D. Regner
  ,
  Katherine Durnan Taylor
  ,
  Andrew L. Bab
  ,
  Caitlin Gibson
  ,
  Amy C. Zimmerman
  ,
  Matthew Ryan
• MarketCheck – Summer 2026
  July 2026
  Ted Hassi
  ,
  Nick S. Kaluk III
  ,
  Marilyn A. Lion
  ,
  Matthew B. Parelman
  ,
  William D. Regner
  ,
  Rick Sofield
  ,
  Andrew L. Bab
  ,
  Robert T. Dura
  ,
  Caitlin Gibson
  ,
  Amy C. Zimmerman
  ,
  Sabrina Y. Hsieh
  ,
  Hannah R. Levine
  ,
  Mackenzie Mendolla
• Debevoise & Plimpton Special Committee Report Issue 11
  March 2026
  Erik J. Andrén
  ,
  Spencer K. Gilbert
  ,
  Elliot Greenfield
  ,
  Emily F. Huang
  ,
  Jonathan E. Levitsky
  ,
  Gordon Moodie
  ,
  Maeve O'Connor
  ,
  William D. Regner
  ,
  Katherine Durnan Taylor
  ,
  Andrew L. Bab
  ,
  Jeffrey J. Rosen
  ,
  Caitlin Gibson
  ,
  Matthew Ryan
  ,
  Amy C. Zimmerman
  ,
  Liz Srulevich
• MarketCheck – Winter 2026
  January 2026
  Catherine Amirfar
  ,
  Michael Bolotin
  ,
  Erin Cleary
  ,
  Emily F. Huang
  ,
  Rafael Kariyev
  ,
  Gregory J. Lyons
  ,
  Gordon Moodie
  ,
  William D. Regner
  ,
  Samantha J. Rowe
  ,
  Paul D. Rubin
  ,
  Peter F.G. Schuur
  ,
  Andrew L. Bab
  ,
  Caitlin Gibson
  ,
  Sarah R. Jacobson
  ,
  Melissa Runsten
  ,
  Ulysses Smith
  ,
  Ronan L. Campbell
  ,
  Christel Y. Tham
  ,
  Jason Zhang
  ,
  Elaine Xie
• “Pharm-to-Table”: The Impact of Direct-to-Consumer Pharmaceutical Sales on Patient Access, Market Dynamics and Investor Strategy
  29 September 2025
  Andrew L. Bab
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Hannah R. Levine
• MarketCheck – Summer 2025
  September 2025
  Catherine Amirfar
  ,
  Andrew L. Bab
  ,
  Charu A. Chandrasekhar
  ,
  Avi Gesser
  ,
  Mark P. Goodman
  ,
  Eric T. Juergens
  ,
  Matthew E. Kaplan
  ,
  Maura Kathleen Monaghan
  ,
  Gordon Moodie
  ,
  Maeve O'Connor
  ,
  Winston M. Paes
  ,
  William D. Regner
  ,
  Paul D. Rubin
  ,
  Shannon Rose Selden
  ,
  Jane Shvets
  ,
  Kristin A. Snyder
  ,
  Rick Sofield
  ,
  William H. Taft V
  ,
  Nicholas Folly
  ,
  Caitlin Gibson
  ,
  Melissa Runsten
  ,
  Natascha Born
  ,
  Jordan Corrente Beck
  ,
  Amy Pereira
• New U.S. Policies Expected to Spur Investor Interest in Domestic Pharmaceutical Manufacturing
  27 August 2025
  Andrew L. Bab
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Hannah R. Levine
• Debevoise & Plimpton Special Committee Report Issue 10
  July 2025
  Erik J. Andrén
  ,
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Elliot Greenfield
  ,
  Emily F. Huang
  ,
  Jonathan E. Levitsky
  ,
  Gordon Moodie
  ,
  Maeve O'Connor
  ,
  William D. Regner
  ,
  Jeffrey J. Rosen
  ,
  Katherine Durnan Taylor
  ,
  Caitlin Gibson
  ,
  Grace Huang
  ,
  Matthew Ryan
• Oregon Legislature Passes House Bill 3410, Signaling Limited Relief for Investors and Management Service Organizations
  22 July 2025
  Andrew L. Bab
  ,
  Spencer K. Gilbert
  ,
  Kevin Rinker
  ,
  Hannah R. Levine
• California Legislature Inches Closer to Imposing Reporting Requirements on Management Service Organizations
  15 July 2025
  Andrew L. Bab
  ,
  Spencer K. Gilbert
  ,
  Kevin Rinker
  ,
  Hannah R. Levine
• The Food and Drug Administration Under the Second Trump Administration
  18 June 2025
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
• Oregon Imposes Significant Restrictions on Private Equity Investment in Healthcare
  12 June 2025
  Andrew L. Bab
  ,
  Spencer K. Gilbert
  ,
  Kevin Rinker
  ,
  Hannah R. Levine
• New Combination Drugs: Assessing the Potential Impact of New CMS Draft Guidance on Pharmaceutical Companies and Investors
  27 May 2025
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Winston M. Paes
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
  ,
  Adriana Kranjac Rielly
• Unpacking President Trump’s New Executive Order on “Most-Favored-Nation” Prescription Drug Pricing
  20 May 2025
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Winston M. Paes
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
  ,
  Adriana Kranjac Rielly
• Unpacking President Trump’s New Executive Order on Prescription Drug Pricing
  24 April 2025
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Winston M. Paes
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
  ,
  Adriana Kranjac Rielly
• Proposed Expansion of California Healthcare Transaction Oversight Takes Aim at Private Equity
  25 March 2025
  Andrew L. Bab
  ,
  Spencer K. Gilbert
  ,
  Kevin Rinker
  ,
  Mackenzie Mendolla
• California Legislature Again Seeks to Restrict Private Equity Investments in Healthcare
  28 February 2025
  Andrew L. Bab
  ,
  Kevin Rinker
  ,
  Hannah R. Levine
  ,
  Mackenzie Mendolla
• Debevoise & Plimpton Special Committee Report Issue 9
  February 2025
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Elliot Greenfield
  ,
  Emily F. Huang
  ,
  Jonathan E. Levitsky
  ,
  Gordon Moodie
  ,
  Maeve O'Connor
  ,
  William D. Regner
  ,
  Jeffrey J. Rosen
  ,
  Katherine Durnan Taylor
  ,
  Caitlin Gibson
  ,
  Erik J. Andrén
  ,
  Matthew Ryan
• Law360: Top 10 Healthcare And Life Sciences Issues To Watch In 2025
  3 February 2025
  Law360
  Paul D. Rubin
  ,
  Maura Kathleen Monaghan
  ,
  Andrew L. Bab
• MarketCheck – Winter 2025
  January 2025
  Andrew L. Bab
  ,
  Emily F. Huang
  ,
  Andrew G. Jamieson
  ,
  Stephen Jordan
  ,
  Jonathan E. Levitsky
  ,
  Gordon Moodie
  ,
  Daniel Priest
  ,
  William D. Regner
  ,
  Katherine Durnan Taylor
  ,
  Robert T. Dura
  ,
  Caitlin Gibson
  ,
  Stuart Hammer
  ,
  Sarah R. Jacobson
  ,
  Weichi Liu
• Top 10 Healthcare and Life Sciences Issues to Watch in 2025
  10 January 2025
  Andrew L. Bab
  ,
  Tim Cornell
  ,
  Avi Gesser
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Erez Liebermann
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Jane Shvets
  ,
  Patrick Taylor
  ,
  Erica S. Weisgerber
  ,
  Carter Burwell
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Lillian Lara
  ,
  Zoe Jacoby
  ,
  Adriana Kranjac Rielly
  ,
  James Lapp
  ,
  Hannah R. Levine
  ,
  Kaitlyn McGill
  ,
  Adam C. Saunders
  ,
  Mackenzie Mendolla
• MarketCheck – Summer 2024
  August 2024
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Jyotin Hamid
  ,
  Emily F. Huang
  ,
  Stephen Jordan
  ,
  Maurizio Levi-Minzi
  ,
  Timothy McIver
  ,
  Frank Mitchell
  ,
  Maura Kathleen Monaghan
  ,
  Jeffrey J. Rosen
  ,
  Zachary H. Saltzman
  ,
  Shannon Rose Selden
  ,
  Matthew J. Sorensen
  ,
  Katherine Durnan Taylor
  ,
  Alison E. Buckley-Serfass
  ,
  Caitlin Gibson
  ,
  Anne-Mette Heemsoth
  ,
  Tricia Bozyk Sherno
  ,
  Jacob W. Stahl
  ,
  Jillian Mulroy Wright
  ,
  Ilya Balabanovsky
  ,
  Marisa Demko
  ,
  Rekha Korlipara Kreider
• Debevoise & Plimpton Special Committee Report Issue 8
  July 2024
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Elliot Greenfield
  ,
  Emily F. Huang
  ,
  Jonathan E. Levitsky
  ,
  Maeve O'Connor
  ,
  William D. Regner
  ,
  Jeffrey J. Rosen
  ,
  Katherine Durnan Taylor
  ,
  Caitlin Gibson
  ,
  Erik J. Andrén
  ,
  Matthew Ryan
• Federal Trade Commission Finalizes Updates to the Health Breach Notification Rule
  20 May 2024
  Andrew L. Bab
  ,
  Avi Gesser
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Johanna N. Skrzypczyk
  ,
  Hannah R. Levine
  ,
  Kaitlyn McGill
• Delaware Supreme Court Holds MFW Inapplicable Based on Banker Conflict Disclosure Deficiencies
  3 May 2024
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Matthew E. Kaplan
  ,
  Jonathan E. Levitsky
  ,
  Maeve O'Connor
  ,
  William D. Regner
• MarketCheck – Spring 2024
  April 2024
  Andrew L. Bab
  ,
  Emily F. Huang
  ,
  Andrew G. Jamieson
  ,
  Jonathan E. Levitsky
  ,
  Katherine Durnan Taylor
  ,
  Caitlin Gibson
• California Lawmakers Target Private Equity and Hedge Fund Investment in Healthcare Facilities
  23 February 2024
  Andrew L. Bab
  ,
  Kevin Rinker
  ,
  Hannah R. Levine
• Private Equity Report: 2024 Outlook
  February 2024
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Andrew L. Bab
  ,
  Paul S. Bird
  ,
  Dominic Blaxill
  ,
  Ezra Borut
  ,
  Geoffrey P. Burgess
  ,
  Andrew J. Ceresney
  ,
  Charu A. Chandrasekhar
  ,
  Luke Dembosky
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Avi Gesser
  ,
  David Grosgold
  ,
  Jyotin Hamid
  ,
  Ted Hassi
  ,
  Morgan J. Hayes
  ,
  Peter J. Irwin
  ,
  Eric T. Juergens
  ,
  Robert B. Kaplan
  ,
  M. Natasha Labovitz
  ,
  Jonathan F. Lewis
  ,
  Sidney P. Levinson
  ,
  Andrew M. Levine
  ,
  Erez Liebermann
  ,
  Timothy McIver
  ,
  Maura Kathleen Monaghan
  ,
  Edwin Northover
  ,
  Brett M. Novick
  ,
  Marc Ponchione
  ,
  Ryan T. Rafferty
  ,
  Julie M. Riewe
  ,
  Kevin Rinker
  ,
  Samantha J. Rowe
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Kevin M. Schmidt
  ,
  Scott B. Selinger
  ,
  Thomas Smith
  ,
  Kristin A. Snyder
  ,
  Steven J. Slutzky
  ,
  Ramya S. Tiller
  ,
  Patricia Volhard
  ,
  Erica S. Weisgerber
  ,
  Alison E. Buckley-Serfass
  ,
  Jennifer R. Cestaro
  ,
  Stuart Hammer
  ,
  Jin-Hyuk Jang
  ,
  Wen-Wei Lai
  ,
  Sheena Paul
  ,
  Melissa Runsten
  ,
  Tricia Bozyk Sherno
  ,
  Ulysses Smith
  ,
  Sergio Torres
  ,
  Elie J. Worenklein
  ,
  Josephine Chen
  ,
  Paul Eastham
  ,
  Yiran Ji
  ,
  Maryam Kanna
  ,
  Perri M. Weinstein
• Chevron Under Fire: What Healthcare and Life Sciences Investors Should Know
  19 January 2024
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Zoe Jacoby
  ,
  Adriana Kranjac Rielly
  ,
  Kaitlyn McGill
• Debevoise & Plimpton Special Committee Report Issue 7
  16 January 2024
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Elliot Greenfield
  ,
  Emily F. Huang
  ,
  Jonathan E. Levitsky
  ,
  Maeve O'Connor
  ,
  William D. Regner
  ,
  Jeffrey J. Rosen
  ,
  Katherine Durnan Taylor
  ,
  Caitlin Gibson
  ,
  Erik J. Andrén
  ,
  Matthew Ryan
• California’s Office of Health Care Affordability Finalizes Health Care Transaction Notice Regulations
  12 January 2024
  Andrew L. Bab
  ,
  Spencer K. Gilbert
  ,
  Kevin Rinker
  ,
  Hannah R. Levine
• Top 10 Healthcare and Life Sciences Issues to Watch in 2024
  4 January 2024
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Ilya Balabanovsky
  ,
  Margaret Howard
  ,
  James Lapp
  ,
  Hannah R. Levine
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
• CMS Announces First Ten Medicare Part D Drugs Subject to Price Negotiations
  6 October 2023
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• California Regulators Publish Draft Regulations on Health Care Pre-Transaction Notice Requirements
  29 August 2023
  Andrew L. Bab
  ,
  Kevin Rinker
  ,
  Hannah R. Levine
• California Seeks to Increase Healthcare Workers’ Minimum Wage to $25/hour
  21 August 2023
  Andrew L. Bab
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• Artificial Intelligence in Healthcare: Balancing Risks and Rewards
  31 July 2023
  Andrew L. Bab
  ,
  Avi Gesser
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• Debevoise & Plimpton Special Committee Report Issue 6
  July 2023
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Elliot Greenfield
  ,
  Emily F. Huang
  ,
  Jonathan E. Levitsky
  ,
  Maeve O'Connor
  ,
  William D. Regner
  ,
  Jeffrey J. Rosen
  ,
  Shannon Rose Selden
  ,
  Jonathan R. Tuttle
  ,
  Caitlin Gibson
  ,
  Erik J. Andrén
  ,
  Matthew Ryan
• FDA Guidance Offers Additional Clarity for Decentralized Clinical Trials
  30 May 2023
  Andrew L. Bab
  ,
  Paul D. Rubin
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• Artificial Intelligence and the Life Sciences Industry: FDA and FTC Regulatory Update
  16 May 2023
  Andrew L. Bab
  ,
  Avi Gesser
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
• Legal Dispute Surrounding Abortion Pill Has Significant Implications for Broader Healthcare Industry
  9 May 2023
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Shannon Rose Selden
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• New York Seeks Review and Approval Authority over Certain Healthcare Transactions
  7 March 2023
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Hannah R. Levine
• Proceed with Caution: Online Tracking Technologies Pose HIPAA Compliance Risks
  2 March 2023
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Hannah R. Levine
• Debevoise & Plimpton Special Committee Report Issue 5
  January 2023
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Elliot Greenfield
  ,
  Emily F. Huang
  ,
  Jonathan E. Levitsky
  ,
  Maeve O'Connor
  ,
  William D. Regner
  ,
  Jeffrey J. Rosen
  ,
  Shannon Rose Selden
  ,
  Jonathan R. Tuttle
  ,
  Caitlin Gibson
  ,
  Erik J. Andrén
  ,
  Matthew Ryan
• Top 15 Healthcare and Life Sciences Issues to Watch in 2023
  9 January 2023
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Jacob W. Stahl
  ,
  Elie J. Worenklein
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
  ,
  Adam C. Saunders
  ,
  Micah A. Rubin
• FTX Collapse Causes SEC to Request Additional Crypto Asset Disclosures
  13 December 2022
  Andrew L. Bab
  ,
  Morgan J. Hayes
  ,
  Sidney P. Levinson
  ,
  Benjamin R. Pedersen
  ,
  Katherine Durnan Taylor
  ,
  Elie J. Worenklein
  ,
  Chris Gallucci
• Implications of the Inflation Reduction Act for Investors in Life Sciences Companies
  November 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
• Private Equity Report Fall 2022, Vol 22, No 3
  November 2022
  Andrew L. Bab
  ,
  Sally Bergmann Hardesty
  ,
  Michael Bolotin
  ,
  Erin Cleary
  ,
  Matthew Dickman
  ,
  Gregory V. Gooding
  ,
  Mark P. Goodman
  ,
  Mark Johnson
  ,
  Henry Lebowitz
  ,
  Maurizio Levi-Minzi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kevin M. Schmidt
  ,
  Scott B. Selinger
  ,
  Ramya S. Tiller
  ,
  Jin-Hyuk Jang
  ,
  Hannah R. Levine
  ,
  Keith J. Slattery
  ,
  Sergio Torres
  ,
  Dominique Trudelle
  ,
  Hadel Alfagir
  ,
  David N. Simpser
• Structuring Options for Addressing the New 1% Excise Tax
  November 2022
  Andrew L. Bab
  ,
  Michael Bolotin
  ,
  Erin Cleary
  ,
  David N. Simpser
• Cautionary Tale from Delaware: Restrictive Covenants Binding Sellers Must Be Narrowly Tailored
  27 October 2022
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Emily F. Huang
  ,
  Maeve O'Connor
  ,
  William D. Regner
  ,
  Jeffrey J. Rosen
  ,
  Caitlin Gibson
• Dealmaking Implications of California’s New Healthcare Cost Monitoring Law
  19 August 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
• Debevoise & Plimpton Special Committee Report Issue 4
  August 2022
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Elliot Greenfield
  ,
  Emily F. Huang
  ,
  Jonathan E. Levitsky
  ,
  Maeve O'Connor
  ,
  William D. Regner
  ,
  Jeffrey J. Rosen
  ,
  Shannon Rose Selden
  ,
  Jonathan R. Tuttle
  ,
  Erik J. Andrén
• Recent SCOTUS Decisions Impacting Healthcare
  3 August 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• FTC Sharpens Focus on Private Equity
  17 June 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Adam C. Saunders
• California Poised to Grant Attorney General Broad Approval Authority over Healthcare Transactions
  16 June 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
• Navigating the Dynamic World of Antitrust Divestitures
  May 2022
  Andrew L. Bab
  ,
  Ted Hassi
• Private Equity Report Spring 2022, Vol 22, No 1
  May 2022
  Catherine Amirfar
  ,
  Andrew L. Bab
  ,
  Megan K. Bannigan
  ,
  David H. Bernstein
  ,
  Alexander R. Cochran
  ,
  Avi Gesser
  ,
  Ted Hassi
  ,
  Eric T. Juergens
  ,
  Matthew E. Kaplan
  ,
  M. Natasha Labovitz
  ,
  Sidney P. Levinson
  ,
  Pierre Maugüé
  ,
  Marc Ponchione
  ,
  Ina Popova
  ,
  Julie M. Riewe
  ,
  Scott B. Selinger
  ,
  Kristin A. Snyder
  ,
  Ramya S. Tiller
  ,
  Richard Ward
  ,
  Erica S. Weisgerber
  ,
  Charu A. Chandrasekhar
  ,
  Nick S. Kaluk III
  ,
  Sheena Paul
  ,
  Christopher Rosekrans
  ,
  Jennifer Wheater
  ,
  Paul Eastham
  ,
  Christopher S. Ford
  ,
  Christine Shu Gilleland
  ,
  Michael C. Godbe
  ,
  Matthew C. Rametta
  ,
  Kate Saba
• CLS Blue Sky Blog: Debevoise & Plimpton Discusses SEC’s Proposed SPAC Rules and Investment Banks
  2 May 2022
  CLS Blue Sky Blog
  Christopher Anthony
  ,
  Andrew L. Bab
  ,
  Morgan J. Hayes
  ,
  William D. Regner
  ,
  Gregory V. Gooding
• The Proposed SPAC Rules and Their Impact on Investment Banks
  27 April 2022
  Christopher Anthony
  ,
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Morgan J. Hayes
  ,
  Peter J. Loughran
  ,
  William D. Regner
  ,
  Steven J. Slutzky
• Harvard Forum on Corporate Governance: Special Committee Report
  19 March 2022
  Harvard Forum on Corporate Governance
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Jeffrey J. Rosen
  ,
  Maeve O'Connor
• Texas Federal Judge Sides with Providers in “No Surprises Act” Ruling
  1 March 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Adriana Kranjac Rielly
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• Debevoise & Plimpton Special Committee Report Issue 3
  February 2022
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Elliot Greenfield
  ,
  Emily F. Huang
  ,
  Jonathan E. Levitsky
  ,
  Maeve O'Connor
  ,
  William D. Regner
  ,
  Jeffrey J. Rosen
  ,
  Shannon Rose Selden
  ,
  Jonathan R. Tuttle
• 2021/2022 Private Equity Year-End Review and Outlook
  January 2022
  Jonathan Adler
  ,
  Catherine Amirfar
  ,
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Andrew L. Bab
  ,
  Geoffrey P. Burgess
  ,
  Ezra Borut
  ,
  Andrew J. Ceresney
  ,
  Jeffrey P. Cunard
  ,
  Alexander R. Cochran
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Morgan J. Hayes
  ,
  Eric T. Juergens
  ,
  Maurizio Levi-Minzi
  ,
  Nicholas P. Pellicani
  ,
  Ryan T. Rafferty
  ,
  Julie M. Riewe
  ,
  Scott B. Selinger
  ,
  Marc Ponchione
  ,
  Thomas Smith
  ,
  Ramya S. Tiller
  ,
  Patricia Volhard
  ,
  Richard Ward
  ,
  Christopher Dortschy
  ,
  Emily F. Huang
  ,
  Jennifer Wheater
  ,
  Dominic Blaxill
  ,
  Robert T. Dura
  ,
  Matthew J. Sacco
  ,
  Sheng Shao
  ,
  Sergio Torres
  ,
  Paul Eastham
  ,
  Christopher Gossage
  ,
  Robert B. Kaplan
  ,
  Sheena Paul
  ,
  John Young
  ,
  Jin-Hyuk Jang
  ,
  Lukas Ott
  ,
  Andrew M. Levine
  ,
  Stuart Hammer
  ,
  Ulysses Smith
  ,
  Luke Dembosky
  ,
  Avi Gesser
  ,
  Peter J. Irwin
  ,
  Ina Popova
  ,
  Samantha J. Rowe
  ,
  M. Natasha Labovitz
  ,
  Sidney P. Levinson
  ,
  Paul D. Rubin
  ,
  Eric Dinallo
  ,
  Marilyn A. Lion
  ,
  Jacob W. Stahl
  ,
  Nicholas F. Potter
  ,
  Melissa Runsten
  ,
  Matthew Mrozek
  ,
  Michael C. Godbe
  ,
  Christel Y. Tham
  ,
  Lisa Wang Lachowicz
  ,
  Yiran Ji
• Debevoise & Plimpton Special Committee Report Issue 2
  September 2021
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Elliot Greenfield
  ,
  Emily F. Huang
  ,
  Jonathan E. Levitsky
  ,
  Maeve O'Connor
  ,
  William D. Regner
  ,
  Jeffrey J. Rosen
  ,
  Shannon Rose Selden
  ,
  Jonathan R. Tuttle
• 2021 Private Equity Midyear Review and Outlook
  22 July 2021
  Jonathan Adler
  ,
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Andrew L. Bab
  ,
  Megan K. Bannigan
  ,
  Sally Bergmann Hardesty
  ,
  David H. Bernstein
  ,
  Paul S. Bird
  ,
  Ezra Borut
  ,
  Geoffrey P. Burgess
  ,
  Matthew Dickman
  ,
  Christopher Dortschy
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Peter A. Furci
  ,
  Avi Gesser
  ,
  Jyotin Hamid
  ,
  Morgan J. Hayes
  ,
  Peter J. Irwin
  ,
  Rafael Kariyev
  ,
  M. Natasha Labovitz
  ,
  Maurizio Levi-Minzi
  ,
  Andrew M. Levine
  ,
  Sidney P. Levinson
  ,
  Jonathan F. Lewis
  ,
  Marc Ponchione
  ,
  Ryan T. Rafferty
  ,
  Paul D. Rubin
  ,
  Zachary H. Saltzman
  ,
  Kevin M. Schmidt
  ,
  Shannon Rose Selden
  ,
  Scott B. Selinger
  ,
  Steven J. Slutzky
  ,
  Ramya S. Tiller
  ,
  Richard Ward
  ,
  Patricia Volhard
  ,
  Franci J. Blassberg
  ,
  Jeffrey P. Cunard
  ,
  Stuart Hammer
  ,
  Jin-Hyuk Jang
  ,
  Sheena Paul
  ,
  Tricia Bozyk Sherno
  ,
  Jacob W. Stahl
  ,
  Jennifer Wheater
  ,
  John Young
  ,
  Dominic Blaxill
  ,
  Robert T. Dura
  ,
  Paul Eastham
  ,
  David J. Hotelling
  ,
  Samuel D. Krawiecz
  ,
  Wen-Wei Lai
  ,
  Robert Maddox
  ,
  Sergio Torres
• The American Rescue Plan Act of 2021: Implications for Healthcare and Life Sciences Companies
  12 March 2021
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• Proposed Elimination of Medicaid Rebate Cap Could Negatively Impact Innovator Pharmaceutical Industry
  11 February 2021
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Biden Takes Aim at Trump Administration Healthcare Policies
  2 February 2021
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• 2020/2021 Private Equity Year End Review and Outlook
  7 January 2021
  Jonathan Adler
  ,
  William D. Regner
  ,
  John W. Rife III
  ,
  Jennifer R. Cestaro
  ,
  Katherine Ashton
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Thomas Smith
  ,
  Ramya S. Tiller
  ,
  Christopher Anthony
  ,
  Kevin M. Schmidt
  ,
  Maurizio Levi-Minzi
  ,
  Geoffrey P. Burgess
  ,
  Dominic Blaxill
  ,
  Wen-Wei Lai
  ,
  Jyotin Hamid
  ,
  Morgan J. Hayes
  ,
  Steven J. Slutzky
  ,
  Richard Ward
  ,
  Jennifer Wheater
  ,
  Paul Eastham
  ,
  Peter A. Furci
  ,
  Rafael Kariyev
  ,
  Samuel D. Krawiecz
  ,
  Andrew L. Bab
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Jyotin Hamid
  ,
  Jonathan F. Lewis
  ,
  Tricia Bozyk Sherno
  ,
  Ezra Borut
  ,
  Jeffrey P. Cunard
  ,
  Marc Ponchione
  ,
  Kenneth J. Berman
  ,
  Patricia Volhard
  ,
  Christopher Dortschy
  ,
  Jin-Hyuk Jang
  ,
  John Young
  ,
  Andrew J. Ceresney
  ,
  Robert B. Kaplan
  ,
  Julie M. Riewe
  ,
  Sally Bergmann Hardesty
  ,
  Scott B. Selinger
  ,
  Stuart Hammer
  ,
  Luke Dembosky
  ,
  Avi Gesser
  ,
  Jim Pastore
  ,
  Megan K. Bannigan
  ,
  David H. Bernstein
  ,
  M. Natasha Labovitz
  ,
  Sidney P. Levinson
  ,
  Peter J. Irwin
  ,
  Paul S. Bird
• Consolidated Appropriations Act: Implications for Healthcare and Life Sciences Companies
  30 December 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• The Trump Administration’s Final Drug Pricing Hurrah—Will It Last?
  24 November 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• COVID-19 Vaccines: FDA Regulatory Timeline and Next Steps Prior to Widespread Distribution
  20 November 2020
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Kevin Rinker
  ,
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• The Potential Impact of a Biden Administration on Life Sciences, Healthcare, and Consumer Product Companies and Investors
  2 November 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Third Circuit Strikes Another Blow Against the FTC’s Preferred Enforcement Power, Setting the Stage for a Supreme Court Showdown
  5 October 2020
  Andrew L. Bab
  ,
  David H. Bernstein
  ,
  Ted Hassi
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
• Trump’s Newest Drug Pricing Executive Order: Still Much More Bark than Bite
  16 September 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• HHS Announces Additional CARES Act Funding for Qualifying Providers
  4 August 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Trump’s New Drug Pricing Executive Orders: Much More Bark Than Bite
  29 July 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• HHS Issues Additional Guidance on Qualifications for CARES Act Funding
  8 May 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Appropriations for Healthcare Providers Related to COVID-19
  30 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• New Appropriation for Healthcare Providers
  24 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• HHS Announces Additional Funding for Healthcare Providers Impacted by COVID-19
  23 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Sponsor Backed PIPEs: COVID-19 and the Race for Liquidity
  22 April 2020
  Andrew L. Bab
  ,
  Gary M. Friedman
  ,
  Gregory V. Gooding
  ,
  Uri Herzberg
  ,
  Jonathan E. Levitsky
  ,
  Sunil William Savkar
  ,
  Kevin M. Schmidt
  ,
  Shannon Rose Selden
  ,
  Katherine Durnan Taylor
  ,
  Steven J. Slutzky
• HHS Distributing $30 Billion in Grants to Medicare Providers
  10 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• CMS Announces Intent to Provide $30 Billion to Medicare Providers
  9 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Rethinking Poison Pills, Again
  9 April 2020
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  William D. Regner
  ,
  Sergio Torres
• Update Regarding Public Health and Social Services Emergency Fund
  6 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The Federal Government Throws a Lifeline to Medicare Providers and Suppliers
  30 March 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• CARES Act: Implications for Healthcare and Life Science Companies and Investors
  27 March 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Indian Pharma: Congress and FDA Continue Scrutiny of Foreign Drug Companies with Heightened Focus on Companies Located in India
  12 February 2020
  Andrew L. Bab
  ,
  Geoffrey P. Burgess
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
• Law360: How Tax Reform Could Impact the Health Care Industry
  15 November 2017
  Andrew L. Bab
  ,
  Peter A. Furci
  ,
  Mark P. Goodman
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl